Año: 2021
Journal Impact Factor (JIF): 19.709
Categoría | Edición | Posición | Cuartil | Tercil | Decil |
---|---|---|---|---|---|
IMMUNOLOGY | SCIE | 8/162 | Q1 | T1 | D1 |
Año:
2021
CiteScore:
26.300
Categoría | Posición | Cuartil | Tercil | Decil |
---|---|---|---|---|
Immunology | 7/213 | Q1 | T1 | D1 |
Immunology and Allergy | 6/200 | Q1 | T1 | D1 |
SJR año:
2021
Factor de Impacto:
4.890
Categoría | Posición | Cuartil | Tercil | Decil |
---|---|---|---|---|
Immunology | 11/214 | Q1 | T1 | D1 |
Immunology and Allergy | 9/204 | Q1 | T1 | D1 |
Agencia | Código de Proyecto |
---|---|
Department of Radiation Oncology at WeillCornell Medicine | - |
Functional Genomics Initiative | - |
Lytix Biopharma | - |
Mantle Cell Lymphoma Research Initiative grant from the Leukemia and Lymphoma Society | - |
Phosplatin | - |
Stand Up to Cancer | ZP-6177 |
US Department of Defense (DoD) Breast Cancer Research Program (BRCP) | BC180476P1 |
# | Autor | Afiliación |
---|---|---|
1 | Jiménez-Cortegana, Carlos | Universidad de Sevilla; Hospital Universitario Virgen Macarena; Weill Cornell Medicine (United States) |
2 | Galassi, Claudia | Weill Cornell Medicine (United States) |
3 | Weill Cornell Medicine; Caryl and Israel Englander Institute for Precision Medicine (United States) |